« Back
Home /
Human VSIG3 Protein, Fc Tag

Human VSIG3 Protein, Fc Tag

Item no.	VS3-H5258-1mg
Manufacturer	ACROBiosystems
Amount	500 ug x 2
Quantity options	100 ug 500 ug x 2
Category	Peptides & Proteins Recombinant Proteins
Type	Proteins Recombinant
Format	Solid
Specific against	Human (Homo sapiens)
Host	HEK293
Conjugate/Tag	Unconjugated, Fc
Purity	95%
Citations	(1) Jang S, et al. 2016. Nat Neurosci. 19(1):84-93. (2) Watanabe T, et al. 2005. Cancer Science. 96(8):498-506. (3) Wang J, et al. 2019. Immunology. 156(1):74-81. (4) Ma J., et al., 2012, J. Biol. Chem. 287:33123-33131.
NCBI	NP_001015887.1
ECLASS 10.1	32160409
ECLASS 11.0	32160409
UNSPSC	12352202
Alias	VSIG3,IgSF11,CXADRL1,Bt-IgSF,CT119
Shipping Condition	Room temperature
Available
Manufacturer - Category	Protein
Manufacturer - Conjugate / Tag	C-Fc, Unconjugated
Shipping Temperature	RT
Storage Conditions	-20°C
Molecular Weight	49.7 kDa
Manufacturer - Format	Powder
Description	VSIG3, also known as IGSF11, BT-IgSF, and CLMP, is a homophilic adhesion molecule that preferentially expressed in the brain. The function of VSIG3 is to stimulate cell growth through homophilic interactions. In clinical, the VSIG3 has been reported to as a novel target for cancer immunotherapy of gastrointestinal and hepatocellular carcinomas. In addition, VSIG-3 is also a ligand of B7 family member VISTA/PD-1H and inhibits human T-cell functions through a novel VSIG-3/VISTA pathway. VSIG-3/VISTA co-inhibitory pathway may provide new strategies for the treatment of human cancers and autoimmune disorders.
Background	VSIG3, also known as IGSF11, BT-IgSF, and CLMP, is a homophilic adhesion molecule that preferentially expressed in the brain. The function of VSIG3 is to stimulate cell growth through homophilic interactions. In clinical, the VSIG3 has been reported to as a novel target for cancer immunotherapy of gastrointestinal and hepatocellular carcinomas. In addition, VSIG-3 is also a ligand of B7 family member VISTA/PD-1H and inhibits human T-cell functions through a novel VSIG-3/VISTA pathway. VSIG-3/VISTA co-inhibitory pathway may provide new strategies for the treatment of human cancers and autoimmune disorders.
Molecule	VSIG3
Exp Region	Leu 23 - Gly 241
Characteristics	This protein carries a human IgG1 Fc tag at the C-terminus. The protein has a calculated MW of 49.7 kDa. The protein migrates as 60-65 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin	1.0 EU per μg
Buffer	Tris with Glycine, Arginine and NaCl, pH7.5
Stability	● -20°C to -70°C for 12 months in lyophilized state ● -70°C for 3 months under sterile conditions after reconstitution._x000D_For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Protectant	trehalose

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

VS3-H5258-1mg-datasheet.pdf

VS3-H5258-1mg-safety-datasheet.pdf